Affiliation:
1. St. Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological); N. N.Petrov National Medical Research Center of Oncology
2. St. Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological)
3. St. Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological); N. N.Petrov National Medical Research Center of Oncology; North-Western State Medical University named after I. I. Mechnikov
Abstract
Purpose of the study. There is the generalized analysis of administration of vinflunine in real clinical practice in St.Petersburg Clinical Scientific and Practical Center of Specialized medical Care (oncological).Materials and methods. This analysis gathered 27 patients with urothelial carcinoma treated using this medicine in St.Petersburg Clinical Scientific and Practical Center of Specialized medical Care (oncological). We assessed efficacy, safety profile of vinflunine in this subset of patients.Results. Clinical efficacy of vinflunine (complete response + partial response + stable disease) was 51,86 %, one patient demonstrated complete response. Median of response duration accounts for 3,4 months. Adverse events were observed in 28,4 %, most of them were 1-2 grades. 2 patients stopped therapy due to adverse events.Conclusion. In our analysis vinflunine was more effective than in randomized clinical trial and other studies from real practice in Europe. Thus, confirm expediency to administer of vinflunine for metastatic urothelial carcinoma.
Subject
Microbiology (medical),Immunology,Immunology and Allergy
Reference9 articles.
1. Malignant neoplasms in Russia in 2019 (morbidity and mortality). Ed. by A.D.Kaprin, V.V.Starinsky, A.O.Shakhzadova. P.A.Hertsen Moscow Oncology Research Institute – Branch of the National Medical Research Radiological Centre. Moscow: 2020, 252 p. (In Russian).
2. Klapheke A, Yap SA, Pan K, Cress RD. Sociodemographic disparities in chemotherapy treatment and impact on survival among patients with metastatic bladder cancer. Urol Oncol. 2018 Jun;36(6):308.e19-308.e25. https://doi.org/10.1016/j.urolonc.2018.03.008
3. von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005 Jul 20;23(21):4602–4608. https://doi.org/10.1200/JCO.2005.07.757
4. Witjes JA, Compérat E, Cowan NC, De Santis M, Gakis G, Lebret T, et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol. 2014 Apr;65(4):778–792. https://doi.org/10.1016/j.eururo.2013.11.046
5. Gladkov OA, Matveev VB, Mitin T, Nosov DA, Popov AM. Practical recommendations for the drug treatment of bladder cancer. Malignant Tumors. 2020;10(3s2-1):542–555. (In Russian). https://doi.org/10.18027/2224-5057-2020-10-3s2-32